(-)-Licarin B
CAS No. 51020-87-2
(-)-Licarin B ( Licarin B )
产品货号. M18686 CAS No. 51020-87-2
1.(-)-Licarin B 具有抗分枝杆菌活性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥377 | 有现货 |
|
| 10MG | ¥591 | 有现货 |
|
| 25MG | ¥917 | 有现货 |
|
| 50MG | ¥1432 | 有现货 |
|
| 100MG | ¥2088 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥348 | 有现货 |
|
生物学信息
-
产品名称(-)-Licarin B
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述1.(-)-Licarin B 具有抗分枝杆菌活性。
-
产品描述Licarin B is a neolignan isolated from seeds of Myristica fragrans.
-
体外实验Licarin B (5 μM, 10 μM, 15 μM. 8 days) moderately increases TG accumulation during adipogenic differentiation and showed partial PPARg agonist activity in 3T3-L1 preadipocytes. Cell Viability Assay Cell Line:3T3-L1 cell.Concentration:1-500 μM.Incubation Time:48 h.Result:Did not cause significant cell death up to 500 μM concentration.Cell Viability Assay Cell Line:3T3-L1 cell.Concentration:5 μM, 10 μM, 15 μM.Incubation Time:8 days (replaced every 2 days).Result:LB at 15 μM concentration significantly promoted adipocyte differentiation and caused intracellular TG accumulation.
-
体内实验——
-
同义词Licarin B
-
通路Others
-
靶点Other Targets
-
受体anti-mycobacterial
-
研究领域Others-Field
-
适应症——
化学信息
-
CAS Number51020-87-2
-
分子量324.37
-
分子式C20H20O4
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (308.29 mM)
-
SMILESCC=CC1=CC2=C(C(=C1)OC)OC(C2C)C3=CC4=C(C=C3)OCO4
-
化学全称5-((2R,3R)-7-methoxy-3-methyl-5-((E)-prop-1-en-1-yl)-2,3-dihydrobenzofuran-2-yl)benzo[d][1,3]dioxole
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
4,5-Dihydropiperlong...
4,5-Dihydropiperlonguminine is a natural product for research related to life sciences.
-
URAT1 inhibitor 7
URAT1 inhibitor 7 (compound 10f) 是一种有效的URAT1抑制剂,IC50为12 nM。URAT1 inhibitor 7 表现出微粒体稳定性(HLM <13 μL/min/mg)。URAT1 inhibitor 7 还抑制CYP2C9,IC50为4.2 μM。URAT1 inhibitor 7 可用于痛风研究。
-
Poricoic acid B
Poricoic Acid B 对 TPA 引起的耳部炎性水肿具有抑制活性。
021-51111890
购物车()
sales@molnova.cn

